In a phase II clinical trial, olaparib combined with paclitaxel has shown a significant improvement in OS in patients with advanced gastric cancer, especially in those with ATM-deficient tumors [123]; however, the subsequent phase III trial with 525 advanced gastric cancer patients did not show a significant improvement in OS with olaparib in the overall or patients with ATM-deficient tumors (12.0 months vs. 10.0 months, hazard ratio = 0.73 and p = 0.25 in the ATM-negative population) [124]. Here, ATM is linked to gastric cancer.